ep recast new report structur
oper profit growth stay healthi clean
deliv organ growth invest
six acquisit combin sale carri
increment top-lin growth connect move cash
earn recast ep vs result old basi
vs add fcf/ni reflect
fcf/ani new basi work capit invest
fcf/ni expect fcf/ni fcf/ani
long term end debt/ebitda even even strong
deal pace share repurchas predominantli
ep beat in-lin guidanc
sale core acq fx vs estim
guidanc ep set vs prior consensu
exclud amort y-o-i sale high-singl digit core
sale grew y-o-i core acq fx om
bp y-o-i bp organ vs estim emg sale
grew y-o-i core acq fx om expand
bp y-o-i vs bp estim
expect organ outlook appli consist segment
throughout segment margin expect flat y-o-i
organ increment margin off-set acquisit
expand om bp despit materi top-lin contribut
acquisit within total revenu growth bp
includ bp acquisit dilut could buffer comparison afford
opportun om upsid vs guid
rais accord new adjust ep
pt remain target fcf-per-share
price-to-earnings given sustain compound model highli probabl
acquir prospect solid return
year price histori
analyst certif import disclosur see disclosur
expect posit investor sentiment given
sustain compound model highli probabl
acquir prospect solid return high /ni convers
strong backlog underwrit outlook attent focus
solid order trend deal flow remain solid robust
recent deal play well oper improv capac
strong convers capit alloc prospect
acceler replenish record backlog
success mitig uncertain tariff headwind
inabl execut difficult organ comp
inabl execut integr acquisit expect
pt base /share price-to-earnings given sustain compound model highli probabl acquir
prospect solid return pt impli potenti upsid includ dividend yield
risk includ weaker global growth includ us weak aerospac oil/gas/chem market inabl
complete/integr acquisit given relianc acquisit supplement top line inabl pass along higher raw materi cost
price aggress consensu ep estim time could hinder stock price perform
exhibit segment result varianc oppenheim estim
compani report oppenheim co inc estim
report ep vs year ago beat in-lin estim
guidanc revenu increas organ acquisit fx vs
estim order increas y-o-i report
segment oper margin expand bp y-o-i vs estim
consolid basi oper margin rose bp y-o-i core bp y-o-i edg
estim exclud acquisit bp
flow/liquid repres /ni vs full-year guid
capital-expenditure total vs last year total debt off-set cash result net
debt/capit vs end
guidanc manag establish ep guidanc vs prior consensu
would reflect new basi y-o-i sale outlook high-singl digit
organ sale expect full-year tax rate capital-expenditure depreci
amort guid ep vs prior consensu
sale high-singl digit
compani report oppenheim co inc estim
electron instrument revenu increas y-o-i organ acquisit
fx match estim aerospac grew high-teen y-o-i organ process increas mid-
teen msd organ power industri grew mid-singl digit lsd organ oper margin
contract bp y-o-i core bp y-o-i match estim
electromechan revenu grew y-o-i organ acquisit fx
vs estim engin solut organ sale increas high-singl digit
oper margin expand bp y-o-i beat estim
annual sale profit segment
compani report oppenheim co inc
quarterli sale profit segment
compani report oppenheim co inc
analysi oper
segment revenu
total segment revenu
segment profit
total segment profit
compani report oppenheim co inc
year end decemb million
good sold
oper profit g/w charg
compani report oppenheim co inc
sale
oper profit g/w charg
compani report oppenheim co inc
year end decemb million
equival
intang invest asset
short-term borrow current portion ltd
average day inventori day hand
compani report oppenheim co inc
consolid statement flow
year end decemb million
inventori current asset
payabl accrual incom tax
net chang work capit
addit pp
proce sale asset discontinu op
purchas busi net cash
net chang short-term borrow
reduct long-term borrow
repurchas common stock
excess tax benefit share-bas payment
proce employe stock option
increas dec
equival -b
equival -e
compani report oppenheim co inc
